Gilead Sciences, Inc.
NEWS
One of the promising experimental drugs being tested to treat COVID-19, the disease caused by the novel coronavirus SARS-Cov2-, is Gilead Sciences’ remdesivir.
A day after it was announced remdesivir had received Orphan Drug designation for treatment of COVID-19 from the U.S. Food and Drug Administration, Gilead Sciences submitted a request for the regulatory agency to rescind that offer after an outcry was raised over the potential for exclusivity for the experimental pandemic treatment.
In order to continue to provide patients with access to the potential treatment, Gilead said it is in the process of transitioning from individual compassionate use requests to expanded access programs.
A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.
The recommended dose of the drug for this age group is based on weight and liver function.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.
Although news of the COVID-19 pandemic has tended to dominate the news cycle, including for the biopharma industry, there were a number of clinical trial announcements last week. Here’s a look.
JOBS
IN THE PRESS